ES2654931T3 - Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos - Google Patents

Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos Download PDF

Info

Publication number
ES2654931T3
ES2654931T3 ES14824711.7T ES14824711T ES2654931T3 ES 2654931 T3 ES2654931 T3 ES 2654931T3 ES 14824711 T ES14824711 T ES 14824711T ES 2654931 T3 ES2654931 T3 ES 2654931T3
Authority
ES
Spain
Prior art keywords
fluoro
phenyl
pyridin
pyrazolo
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14824711.7T
Other languages
English (en)
Spanish (es)
Inventor
Robert L. Hudkins
Allison L. Zulli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ignyta Inc
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Application granted granted Critical
Publication of ES2654931T3 publication Critical patent/ES2654931T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES14824711.7T 2013-12-26 2014-12-18 Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos Active ES2654931T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26
US201361920819P 2013-12-26
PCT/US2014/071040 WO2015100117A1 (en) 2013-12-26 2014-12-18 Pyrazolo[1,5-a]pyridine derivatives and methods of their use

Publications (1)

Publication Number Publication Date
ES2654931T3 true ES2654931T3 (es) 2018-02-15

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14824711.7T Active ES2654931T3 (es) 2013-12-26 2014-12-18 Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos

Country Status (22)

Country Link
US (2) US9914731B2 (enExample)
EP (2) EP3087070B1 (enExample)
JP (1) JP2017500362A (enExample)
KR (1) KR20160110390A (enExample)
CN (1) CN106029661B (enExample)
AU (1) AU2014370186A1 (enExample)
BR (1) BR112016015057A2 (enExample)
CA (1) CA2934667A1 (enExample)
CL (1) CL2016001604A1 (enExample)
DK (1) DK3087070T3 (enExample)
EA (2) EA029757B1 (enExample)
ES (1) ES2654931T3 (enExample)
HU (1) HUE037579T2 (enExample)
IL (1) IL246311A0 (enExample)
MX (1) MX2016008445A (enExample)
NO (1) NO3014707T3 (enExample)
PH (1) PH12016501232A1 (enExample)
PL (1) PL3087070T3 (enExample)
PT (1) PT3087070T (enExample)
SG (1) SG11201605207PA (enExample)
SI (1) SI3087070T1 (enExample)
WO (1) WO2015100117A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210177T1 (hr) * 2015-07-16 2021-03-19 Array Biopharma, Inc. Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
EP3719012B1 (en) * 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
PL3842425T3 (pl) * 2018-08-24 2024-08-19 Transthera Sciences (Nanjing), Inc. Nowy inhibitor będący pochodną chinoliny
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
EP4029862A4 (en) * 2019-09-06 2023-10-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021197276A1 (en) 2020-03-30 2021-10-07 Hutchison Medipharma Limited Amide compounds and uses thereof
JP7802077B2 (ja) * 2021-07-13 2026-01-19 日本曹達株式会社 ウラシル化合物の製造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l，2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
WO2025034912A2 (en) 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Compounds for fgfr inhibition
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CA2645137A1 (en) * 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
WO2008072634A1 (ja) * 2006-12-12 2008-06-19 Takeda Pharmaceutical Company Limited 縮合複素環化合物
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
SI2719699T1 (sl) * 2009-12-31 2015-12-31 Hutchison Medipharma Limited Določeni triazolopirazini, njihovi sestavki in načini njihove uporabe
CN103492384B (zh) * 2011-02-25 2016-05-11 诺华股份有限公司 作为trk抑制剂的化合物和组合物
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
US9283225B2 (en) * 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
WO2013043715A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
MX342241B (es) * 2011-11-14 2016-09-21 Ignyta Inc Derivados de uracilo como inhibidores de la quinasa axl y c-met.
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
US20180148447A1 (en) 2018-05-31
EA201890061A2 (ru) 2018-05-31
HUE037579T2 (hu) 2018-09-28
PH12016501232A1 (en) 2016-08-15
DK3087070T3 (en) 2017-12-04
EA201691164A1 (ru) 2016-12-30
EP3087070B1 (en) 2017-11-08
IL246311A0 (en) 2016-08-02
CN106029661B (zh) 2017-11-03
CL2016001604A1 (es) 2017-05-26
CN106029661A (zh) 2016-10-12
EP3087070A1 (en) 2016-11-02
US9914731B2 (en) 2018-03-13
PL3087070T3 (pl) 2018-03-30
NO3014707T3 (enExample) 2018-01-06
SI3087070T1 (en) 2018-01-31
US20160318929A1 (en) 2016-11-03
BR112016015057A2 (pt) 2017-08-08
MX2016008445A (es) 2016-10-28
EA201890061A3 (ru) 2018-09-28
KR20160110390A (ko) 2016-09-21
WO2015100117A1 (en) 2015-07-02
SG11201605207PA (en) 2016-07-28
AU2014370186A2 (en) 2016-07-21
JP2017500362A (ja) 2017-01-05
AU2014370186A1 (en) 2016-07-14
EA029757B1 (ru) 2018-05-31
EP3309160A1 (en) 2018-04-18
CA2934667A1 (en) 2015-07-02
PT3087070T (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
ES2654931T3 (es) Derivados de pirazolo[1,5-a]piridina y procedimientos de uso de los mismos
KR102374844B1 (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
ES2615238T3 (es) Derivados de tetrahidroquinolinas como inhibidores de bromodominio
ES2873515T3 (es) Derivado de quinolona, sal o estereoisómero del mismo farmacéuticamente aceptable, como inhibidor de AXL
ES2424651T3 (es) Nuevo derivado de piridina y derivado de pirimidina (3)
RU2582610C2 (ru) Производные хинолина и содержащие их ингибиторы melk
ES2368876T3 (es) Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
ES2472323T3 (es) Compuestos de piridina
ES2852351T3 (es) Pirrolamidas como inhibidores de la integrina alfa V
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
ES2375735T3 (es) Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
CN113773308A (zh) Rho激酶抑制剂
ES2842230T3 (es) Compuestos terapéuticos como inhibidores del receptor de orexina-1
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
HK1217482A1 (en) Enzyme modulators and therapies
MX2014008647A (es) Compuesto de pirazin-carboxamida.
AU2003261807A1 (en) Azaarene derivatives
CN104507933A (zh) 氨基喹唑啉和吡啶并嘧啶衍生物
KR20130036201A (ko) 헤타릴아미노나프티리딘
Liu et al. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase
CN111918863B (zh) 杂环化合物
CN112074511A (zh) 取代的苯并二唑及其在治疗中的用途
HK40064586A (en) Rho kinase inhibitors
HK40062730A (en) Rho kinase inhibitors
HK40062732A (en) Rho kinase inhibitors